Banyan Biomarkers, Inc.

Banyan Biomarkers, Inc. specializes in developing innovative diagnostic solutions for neurological conditions, focusing on improving patient outcomes through advanced biomarker technology and rapid testing capabilities. Banyan Biomarkers, Inc. was founded in 2002 and operates out of San Diego, US.

The company is dedicated to the development of diagnostic tests that enhance the detection of brain injuries. Ronald Hayes is one of the founders of the company. The firm has completed a total of 5 deals with its most recent funding round occurring on December 20, 2018, where it raised USD 2. 23 mn in VENTURE DEBT financing.

Overall, the company has successfully raised USD 1. 5 mn. Banyan Biomarkers, Inc. offers diagnostic tests specifically designed for neurological conditions, with a strong emphasis on analyzing biomarkers associated with brain injuries.

Their products aim to enable healthcare providers to make more informed decisions regarding patient care by providing accurate, rapid assessments of neurological conditions. The company's offerings are utilized by medical professionals in various regions, including North America and parts of Europe, where reliable diagnostic tools are critical for effective treatment. Banyan Biomarkers, Inc. generates revenue through the sale of its diagnostic tests and related services.

The company's revenue model primarily includes direct sales to healthcare institutions, which allows for access to essential testing and support services. The commercial contracts generally encompass both product sales and ongoing technical support, ensuring that clients can effectively utilize the diagnostic capabilities of the company’s solutions. Looking forward, Banyan Biomarkers, Inc. plans to enhance its product line with new diagnostic tests aimed at additional neurological conditions by the end of 2023.

These innovations will leverage advancements in biomarker research to expand their market reach. The company also aims to enter European markets further, targeting specific countries like Germany and the UK by 2024. The funding raised in December 2018, amounting to USD 2. 23 mn, will be allocated towards research and development for these upcoming products as well as expanding their marketing efforts in new regions.